company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q2,2009-04-01,2009-06-30,2010-07-29 15:12:59+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,125864000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q2,2009-04-01,2009-06-30,2010-07-29 15:12:59+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,125864000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q2,2009-04-01,2009-06-30,2010-07-29 15:12:59+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,125864000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q2,2009-04-01,2009-06-30,2010-07-29 15:12:59+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5590000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q2,2009-04-01,2009-06-30,2010-07-29 15:12:59+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5590000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q2,2009-04-01,2009-06-30,2010-07-29 15:12:59+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,120274000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q2,2009-04-01,2009-06-30,2010-07-29 15:12:59+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2162000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q2,2009-04-01,2009-06-30,2010-07-29 15:12:59+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2162000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q2,2009-04-01,2009-06-30,2010-07-29 15:12:59+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,118422000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q2,2009-04-01,2009-06-30,2010-07-29 15:12:59+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,41185000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q2,2009-04-01,2009-06-30,2010-07-29 15:12:59+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,77237000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q2,2009-04-01,2009-06-30,2010-07-29 15:12:59+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,77237000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q2,2009-04-01,2009-06-30,2010-07-29 15:12:59+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,77237000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q2,2009-04-01,2009-06-30,2010-07-29 15:12:59+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,119357000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q2,2009-04-01,2009-06-30,2010-07-29 15:12:59+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.65
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q2,2009-04-01,2009-06-30,2010-07-29 15:12:59+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,169566000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q2,2009-04-01,2009-06-30,2010-07-29 15:12:59+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.47
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q2,2009-04-01,2009-06-30,2010-07-29 15:12:59+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,118800000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q2,2009-04-01,2009-06-30,2010-07-29 15:12:59+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.65
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q2,2009-04-01,2009-06-30,2010-07-29 15:12:59+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:07:08+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,71446000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:07:08+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,71446000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:07:08+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,71446000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:07:08+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5255000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:07:08+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5255000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:07:08+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,66191000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:07:08+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2782000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:07:08+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2782000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:07:08+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,63623000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:07:08+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,17217000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:07:08+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,46406000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:07:08+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,46406000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:07:08+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,46406000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:07:08+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,119411000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:07:08+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.39
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:07:08+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,168576000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:07:08+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.29
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:07:08+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,119000000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:07:08+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.39
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2009.0,Q3,2009-07-01,2009-09-30,2010-11-09 16:07:08+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q1,2010-01-01,2010-03-31,2011-04-28 14:35:42+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,62061000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q1,2010-01-01,2010-03-31,2011-04-28 14:35:42+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,62061000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q1,2010-01-01,2010-03-31,2011-04-28 14:35:42+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,62061000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q1,2010-01-01,2010-03-31,2011-04-28 14:35:42+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9410000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q1,2010-01-01,2010-03-31,2011-04-28 14:35:42+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9410000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q1,2010-01-01,2010-03-31,2011-04-28 14:35:42+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,52651000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q1,2010-01-01,2010-03-31,2011-04-28 14:35:42+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,12527000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q1,2010-01-01,2010-03-31,2011-04-28 14:35:42+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-12527000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q1,2010-01-01,2010-03-31,2011-04-28 14:35:42+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,40204000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q1,2010-01-01,2010-03-31,2011-04-28 14:35:42+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,14197000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q1,2010-01-01,2010-03-31,2011-04-28 14:35:42+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,26007000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q1,2010-01-01,2010-03-31,2011-04-28 14:35:42+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,26007000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q1,2010-01-01,2010-03-31,2011-04-28 14:35:42+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,26007000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q1,2010-01-01,2010-03-31,2011-04-28 14:35:42+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,119525000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q1,2010-01-01,2010-03-31,2011-04-28 14:35:42+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.22
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q1,2010-01-01,2010-03-31,2011-04-28 14:35:42+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,184308000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q1,2010-01-01,2010-03-31,2011-04-28 14:35:42+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.15
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q1,2010-01-01,2010-03-31,2011-04-28 14:35:42+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,118200000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q1,2010-01-01,2010-03-31,2011-04-28 14:35:42+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.22
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q1,2010-01-01,2010-03-31,2011-04-28 14:35:42+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q2,2010-04-01,2010-06-30,2011-07-29 17:06:18+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,120343000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q2,2010-04-01,2010-06-30,2011-07-29 17:06:18+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,120343000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q2,2010-04-01,2010-06-30,2011-07-29 17:06:18+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,120343000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q2,2010-04-01,2010-06-30,2011-07-29 17:06:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8820000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q2,2010-04-01,2010-06-30,2011-07-29 17:06:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8820000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q2,2010-04-01,2010-06-30,2011-07-29 17:06:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,111523000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q2,2010-04-01,2010-06-30,2011-07-29 17:06:18+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,27887000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q2,2010-04-01,2010-06-30,2011-07-29 17:06:18+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,90000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q2,2010-04-01,2010-06-30,2011-07-29 17:06:18+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-27797000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q2,2010-04-01,2010-06-30,2011-07-29 17:06:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,83726000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q2,2010-04-01,2010-06-30,2011-07-29 17:06:18+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,33588000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q2,2010-04-01,2010-06-30,2011-07-29 17:06:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,50138000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q2,2010-04-01,2010-06-30,2011-07-29 17:06:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,50138000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q2,2010-04-01,2010-06-30,2011-07-29 17:06:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,50138000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q2,2010-04-01,2010-06-30,2011-07-29 17:06:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,119536000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q2,2010-04-01,2010-06-30,2011-07-29 17:06:18+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.42
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q2,2010-04-01,2010-06-30,2011-07-29 17:06:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,173398000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q2,2010-04-01,2010-06-30,2011-07-29 17:06:18+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.3
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q2,2010-04-01,2010-06-30,2011-07-29 17:06:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,119400000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q2,2010-04-01,2010-06-30,2011-07-29 17:06:18+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.42
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q2,2010-04-01,2010-06-30,2011-07-29 17:06:18+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:30:57+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,86442000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:30:57+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,86442000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:30:57+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,86442000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:30:57+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11110000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:30:57+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11110000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:30:57+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,75332000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:30:57+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,12282000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:30:57+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,167000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:30:57+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-12115000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:30:57+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,63217000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:30:57+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,23028000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:30:57+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,40189000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:30:57+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,40189000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:30:57+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,40189000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:30:57+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,127479000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:30:57+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.32
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:30:57+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,172217000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:30:57+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.24
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:30:57+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,125600000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:30:57+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.32
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q3,2010-07-01,2010-09-30,2011-11-09 16:30:57+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.5
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,76129000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,76129000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,76129000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12056000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,92500000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,104556000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-28427000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,8481000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,468000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-257000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-8270000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-36777000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-12317000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-24460000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-24460000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-24460000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,126578000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.23
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,178801000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.15
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,125900000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.23
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2010.0,Q4,2010-10-01,2010-12-31,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,-0.5
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 16:05:58+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,83336000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 16:05:58+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,83336000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 16:05:58+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,83336000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 16:05:58+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5779000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 16:05:58+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5779000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 16:05:58+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,77557000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 16:05:58+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9154000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 16:05:58+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,175000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 16:05:58+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-8979000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 16:05:58+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,68578000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 16:05:58+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,24033000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 16:05:58+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,44545000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 16:05:58+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,44545000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 16:05:58+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,44545000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 16:05:58+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,139640000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 16:05:58+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.32
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 16:05:58+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,189954000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 16:05:58+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.25
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 16:05:58+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,139200000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 16:05:58+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.32
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q1,2011-01-01,2011-03-31,2012-05-03 16:05:58+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.6
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 16:11:03+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,122127000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 16:11:03+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,122127000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 16:11:03+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,122127000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 16:11:03+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3776000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 16:11:03+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3776000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 16:11:03+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,118351000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 16:11:03+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,10546000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 16:11:03+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,157000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 16:11:03+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-10389000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 16:11:03+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,107962000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 16:11:03+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,37976000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 16:11:03+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,69986000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 16:11:03+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,69986000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 16:11:03+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,69986000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 16:11:03+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,139650000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 16:11:03+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.5
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 16:11:03+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,186060000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 16:11:03+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.38
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 16:11:03+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,140000000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 16:11:03+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.5
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q2,2011-04-01,2011-06-30,2012-08-02 16:11:03+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 16:11:00+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,83770000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 16:11:00+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,83770000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 16:11:00+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,83770000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 16:11:00+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3960000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 16:11:00+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3960000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 16:11:00+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,79810000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 16:11:00+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9007000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 16:11:00+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,130000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 16:11:00+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-8877000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 16:11:00+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,70933000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 16:11:00+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,25017000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 16:11:00+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,45916000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 16:11:00+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,45916000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 16:11:00+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,45916000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 16:11:00+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,139680000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 16:11:00+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.33
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 16:11:00+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,167019000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 16:11:00+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.28
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 16:11:00+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,139100000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 16:11:00+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.33
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q3,2011-07-01,2011-09-30,2012-11-05 16:11:00+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q4,2011-10-01,2011-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,72808000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,72808000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,72808000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4823000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,4823000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,67985000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,8161000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,131000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-8030000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,59955000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,21013000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,38942000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,38942000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,38942000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,139663000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.28
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,177441000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.24
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,139400000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.28
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 16:03:06+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,77344000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 16:03:06+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,77344000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 16:03:06+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,77344000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 16:03:06+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6945000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 16:03:06+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6945000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 16:03:06+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,70399000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 16:03:06+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,8700000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 16:03:06+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,90000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 16:03:06+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-8610000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 16:03:06+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,61789000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 16:03:06+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,21605000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 16:03:06+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,40184000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 16:03:06+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,40184000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 16:03:06+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,40184000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 16:03:06+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,139680000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 16:03:06+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.29
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 16:03:06+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,140204000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 16:03:06+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.29
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 16:03:06+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,138600000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 16:03:06+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.29
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q1,2012-01-01,2012-03-31,2013-05-09 16:03:06+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.6
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 16:02:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,125904000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 16:02:56+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,125904000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 16:02:56+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,125904000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 16:02:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5145000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 16:02:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5145000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 16:02:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,120759000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 16:02:56+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,7872000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 16:02:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,428000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 16:02:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-7444000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 16:02:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,113315000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 16:02:56+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,39813000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 16:02:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,73502000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 16:02:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,73502000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 16:02:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,73502000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 16:02:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,139683000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 16:02:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.53
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 16:02:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,142213000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 16:02:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.52
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 16:02:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,138700000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 16:02:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.53
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q2,2012-04-01,2012-06-30,2013-08-08 16:02:56+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:03:19+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,85231000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:03:19+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,85231000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:03:19+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,85231000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:03:19+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5647000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:03:19+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5647000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:03:19+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,79584000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:03:19+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6514000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:03:19+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1867000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:03:19+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4647000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:03:19+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,74937000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:03:19+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,26362000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:03:19+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,48575000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:03:19+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,48575000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:03:19+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,48575000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:03:19+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,139715000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:03:19+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.35
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:03:19+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,149626000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:03:19+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.32
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:03:19+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,138800000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:03:19+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.35
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 16:03:19+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,92401000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,92401000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,92401000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7732000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7732000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,84669000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5950000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-1627000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-7577000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,77092000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,27684000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,49408000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,49408000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,49408000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,139711000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.35
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,146403000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.32
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,139300000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.35
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,91847000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,91847000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,91847000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7186000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7186000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,84661000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6000000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,3838000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2162000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,82499000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,29028000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,53471000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,53471000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,53471000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,139816000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.38
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,149101000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.36
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,140700000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.38
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:04:14+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.6
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q2,2013-04-01,2013-06-30,2014-08-18 16:01:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,148520000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q2,2013-04-01,2013-06-30,2014-08-18 16:01:50+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,148520000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q2,2013-04-01,2013-06-30,2014-08-18 16:01:50+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,148520000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q2,2013-04-01,2013-06-30,2014-08-18 16:01:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6783000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q2,2013-04-01,2013-06-30,2014-08-18 16:01:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6783000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q2,2013-04-01,2013-06-30,2014-08-18 16:01:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,141737000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q2,2013-04-01,2013-06-30,2014-08-18 16:01:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6051000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q2,2013-04-01,2013-06-30,2014-08-18 16:01:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,60000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q2,2013-04-01,2013-06-30,2014-08-18 16:01:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-5991000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q2,2013-04-01,2013-06-30,2014-08-18 16:01:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,135746000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q2,2013-04-01,2013-06-30,2014-08-18 16:01:50+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,42004000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q2,2013-04-01,2013-06-30,2014-08-18 16:01:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,93742000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q2,2013-04-01,2013-06-30,2014-08-18 16:01:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,93742000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q2,2013-04-01,2013-06-30,2014-08-18 16:01:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,93742000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q2,2013-04-01,2013-06-30,2014-08-18 16:01:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,139825000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q2,2013-04-01,2013-06-30,2014-08-18 16:01:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.67
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q2,2013-04-01,2013-06-30,2014-08-18 16:01:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,152224000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q2,2013-04-01,2013-06-30,2014-08-18 16:01:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.62
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q2,2013-04-01,2013-06-30,2014-08-18 16:01:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,139900000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q2,2013-04-01,2013-06-30,2014-08-18 16:01:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.67
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q2,2013-04-01,2013-06-30,2014-08-18 16:01:50+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:16:20+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,100178000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:16:20+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,100178000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:16:20+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,100178000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:16:20+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7925000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:16:20+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7925000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:16:20+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,92253000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:16:20+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6118000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:16:20+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,53000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:16:20+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-6065000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:16:20+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,86188000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:16:20+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,29963000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:16:20+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,56225000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:16:20+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,56225000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:16:20+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,56225000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:16:20+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,139848000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:16:20+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.4
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:16:20+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,154593000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:16:20+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.36
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:16:20+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,140600000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:16:20+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.4
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 16:16:20+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,115715000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,115715000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,115715000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7861000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7861000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,107854000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6702000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-3709000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-10411000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,97443000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,36351000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,61092000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,61092000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,61092000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,139842000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.44
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,159343000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.32
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,140000000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.44
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 16:02:08+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,136804000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 16:02:08+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,136804000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 16:02:08+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,136804000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 16:02:08+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4582000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 16:02:08+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,4582000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 16:02:08+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,132222000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 16:02:08+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,16668000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 16:02:08+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,50000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 16:02:08+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-16618000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 16:02:08+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,115604000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 16:02:08+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,42721000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 16:02:08+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,72883000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 16:02:08+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,72883000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 16:02:08+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,72883000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 16:02:08+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,151198000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 16:02:08+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.48
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 16:02:08+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,164571000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 16:02:08+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.44
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 16:02:08+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,151800000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 16:02:08+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.48
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 16:02:08+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.6
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 16:08:58+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,162752000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 16:08:58+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,162752000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 16:08:58+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,162752000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 16:08:58+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6920000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 16:08:58+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6920000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 16:08:58+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,155832000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 16:08:58+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9858000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 16:08:58+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,82000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 16:08:58+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-9776000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 16:08:58+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,146056000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 16:08:58+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,54001000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 16:08:58+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,92055000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 16:08:58+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,92055000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 16:08:58+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,92055000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 16:08:58+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,160256000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 16:08:58+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.57
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 16:08:58+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,177228000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 16:08:58+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.52
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 16:08:58+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,161500000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 16:08:58+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.57
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q2,2014-04-01,2014-06-30,2015-08-05 16:08:58+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:03:09+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,164594000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:03:09+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,164594000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:03:09+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,164594000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:03:09+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5686000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:03:09+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5686000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:03:09+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,158908000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:03:09+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9387000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:03:09+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,75000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:03:09+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-9312000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:03:09+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,149596000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:03:09+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,47361000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:03:09+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,102235000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:03:09+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,102235000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:03:09+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,102235000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:03:09+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,160268000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:03:09+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.64
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:03:09+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,166894000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:03:09+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.61
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:03:09+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,159700000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:03:09+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.64
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 16:03:09+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,117075000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,117075000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,117075000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,17726000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17726000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,99349000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9441000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,108000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-9333000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,90016000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,34945000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,55071000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,55071000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,55071000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,158224000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.35
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,173110000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.29
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,158000000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.35
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:10:16+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,149706000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:10:16+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,149706000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:10:16+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,149706000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:10:16+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7666000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:10:16+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7666000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:10:16+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,142040000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:10:16+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,8610000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:10:16+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,86000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:10:16+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-8524000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:10:16+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,133516000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:10:16+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,49018000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:10:16+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,84498000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:10:16+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,84498000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:10:16+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,84498000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:10:16+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,162829000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:10:16+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.52
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:10:16+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,170412000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:10:16+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.5
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:10:16+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,162500000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:10:16+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.52
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q1,2015-01-01,2015-03-31,2016-05-04 16:10:16+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.6
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,138066000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,138066000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,138066000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7429000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7429000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,130637000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,7199000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,121000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-7078000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,123559000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,45295000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,78264000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,78264000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,78264000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,163544000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.48
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,165384000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.47
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,163100000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.48
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:37+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,124618000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,124618000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,124618000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8450000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8450000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,116168000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5901000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,87000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-5814000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,110354000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,40895000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,69459000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,69459000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,69459000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,163560000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.42
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,163742000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.42
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,165400000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.42
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 17:23:25+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,178058000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,178058000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,178058000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12545000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,3979000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,16524000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,161534000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-1101000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,74000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1175000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,162709000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,62135000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,100574000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,100574000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,100574000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,163386000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.62
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,163554000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.64
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,163100000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.62
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,103124000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,103124000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,103124000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9846000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9846000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,93278000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4550000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,113000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4437000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,88841000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,32954000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,55887000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,55887000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,55887000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,163701000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.34
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,163835000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.34
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,164400000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.34
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 16:23:00+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.05
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21047000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21047000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,21047000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6951000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,2959000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9910000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,11137000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4461000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,129000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4332000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,6805000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2657000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4148000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4148000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4148000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,163791000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.03
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,164029000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.03
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,138300000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.03
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 17:04:55+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.05
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,45440000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,45440000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,8567000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,8567000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,36873000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12576000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,2584000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1766000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,1442000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18368000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,18505000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4971000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,212000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4759000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,13746000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,6552000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,7194000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,7194000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-47000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,7241000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,163745000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.04
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,163992000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.04
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,181000000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.04
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q1,2017-01-01,2017-03-31,2017-05-03 16:23:00+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,143835000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,143835000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,10663000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,10663000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,133172000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11288000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,3616000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4281000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,1207000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20392000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,112780000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5015000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,276000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,6271000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1532000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,114312000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,53873000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,60439000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,60439000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,60439000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,155654000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.39
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,156394000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.39
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,155000000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.39
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2017.0,Q2,2017-04-01,2017-06-30,2017-08-03 17:04:55+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,38518000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,38518000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,10566000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,10566000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,27952000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11661000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,5513000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,793000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,6293000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-600000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,23660000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4292000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3585000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1914000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1671000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2621000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1019000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1602000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1602000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1602000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,151473000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.01
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,152579000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.01
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,160200000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:07:03+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.01
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,46575000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,46575000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,14524000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,14524000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,32051000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,14529000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,5385000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,684000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,6384000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-22135000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,152330000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,157177000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-125126000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2811000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1376000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1435000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-126561000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-14265000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-112296000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-112296000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-112296000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,146923000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.76
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,146923000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.76
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,147800000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 16:31:07+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.76
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,67898000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,67898000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,11926000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,11926000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,55972000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,13211000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,3469000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,672000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,1577000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,302000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19231000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,36741000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2866000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1581000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1285000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,35456000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,9900000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,25556000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,25556000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,25556000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,143171000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.18
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,144224000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.18
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,142000000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 16:14:13+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.18
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6696000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6696000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3800000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3800000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2896000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8313000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,1574000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,910000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,318000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11115000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-8219000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2955000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1874000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1081000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9300000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-848000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-8452000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,15069000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,6617000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-63000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,6680000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,128799000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.05
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,128799000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.05
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,133600000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 21:32:36+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.05
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,-22526000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,-22526000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,12348000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,12348000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-34874000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10483000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,2073000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,886000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,1598000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15040000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-49914000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2984000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,47137000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,44153000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5761000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1247000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4514000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4514000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-95000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4419000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,118285000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.04
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,118285000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.04
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,110500000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:31:07+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.04
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,44165000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,44165000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,15033000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,15033000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,29132000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12092000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,1712000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4310000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,1575000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19689000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,9443000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6911000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,4936000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-27378000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-29353000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19910000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1944000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-17966000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-17966000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-182000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-17784000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,112986000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.16
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,112986000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.16
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,111200000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 16:14:13+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.16
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,26422000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,26422000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,22438000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,22438000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3984000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,14710000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,3123000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1202000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,2815000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,33258000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,55108000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-51124000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6984000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-47917000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,67256000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,12355000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-38769000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,990000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-39759000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-15069000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-54828000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,60000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-54888000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,118631000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.44
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,118631000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.44
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,119300000.0
PDL BioPharma Inc,PDLI,FE4K0NQFI4D86DSOL165,0000882104,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.44
